BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 41 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q1 2022. The put-call ratio across all filers is 0.59 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $1,000 | 0.0% | 500 | 0.0% | 0.00% | – |
Q1 2022 | $1,000 | -50.0% | 500 | 0.0% | 0.00% | – |
Q4 2021 | $2,000 | +100.0% | 500 | 0.0% | 0.00% | – |
Q3 2021 | $1,000 | 0.0% | 500 | 0.0% | 0.00% | – |
Q2 2021 | $1,000 | 0.0% | 500 | 0.0% | 0.00% | – |
Q1 2021 | $1,000 | -50.0% | 500 | 0.0% | 0.00% | – |
Q4 2020 | $2,000 | -97.0% | 500 | -87.5% | 0.00% | – |
Q3 2020 | $67,000 | +52.3% | 4,000 | 0.0% | 0.00% | – |
Q2 2020 | $44,000 | +144.4% | 4,000 | 0.0% | 0.00% | – |
Q1 2020 | $18,000 | +5.9% | 4,000 | 0.0% | 0.00% | – |
Q4 2019 | $17,000 | +13.3% | 4,000 | 0.0% | 0.00% | – |
Q3 2019 | $15,000 | +15.4% | 4,000 | +14.3% | 0.00% | – |
Q2 2019 | $13,000 | -13.3% | 3,500 | 0.0% | 0.00% | – |
Q1 2019 | $15,000 | +25.0% | 3,500 | 0.0% | 0.00% | – |
Q4 2018 | $12,000 | -7.7% | 3,500 | 0.0% | 0.00% | – |
Q3 2018 | $13,000 | 0.0% | 3,500 | 0.0% | 0.00% | – |
Q2 2018 | $13,000 | +18.2% | 3,500 | 0.0% | 0.00% | – |
Q1 2018 | $11,000 | -15.4% | 3,500 | 0.0% | 0.00% | – |
Q4 2017 | $13,000 | -7.1% | 3,500 | 0.0% | 0.00% | – |
Q3 2017 | $14,000 | – | 3,500 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ikarian Capital, LLC | 189,935 | $311,494 | 0.08% |
ABNER HERRMAN & BROCK LLC | 280,000 | $459 | 0.07% |
Weaver Consulting Group | 65,947 | $108,153 | 0.06% |
S.C. Financial Services, Inc. | 25,372 | $41,610 | 0.03% |
JMAC ENTERPRISES LLC | 40,430 | $66,305 | 0.02% |
Weaver Consulting Group | 53,500 | $10,047 | 0.01% |
IFP Advisors, Inc | 26,650 | $139 | 0.00% |
Bangor Savings Bank | 4,000 | $7 | 0.00% |
INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC | 3,000 | $4,920 | 0.00% |
BOOTHBAY FUND MANAGEMENT, LLC | 19,098 | $31,321 | 0.00% |